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Introduction
Opioid receptors are G protein-coupled receptors (GPCRs) that are widely expressed throughout the body and regulate a diverse array of physiological functions, including pain sensation, respiration, mood and reward. Opioid receptors are activated by endogenous opioids, such as endorphins and enkephalins, by natural products such as Papaver somniferum (opium) and Salvia divinorum, and by synthetic opioids such as fentanyl and methadone. The current clinically-used opioids provide strong analgesic support in operative and post-operative settings, but their use is also associated with adverse effects including the development of tolerance, constipation, opioid use disorder and respiratory depression, which can ultimately prove fatal.
Studies utilizing β-arrestin 2 knockout mice revealed that certain opioid side effects may be associated with β-arrestin 2 recruitment upon µ-opioid receptor activation (Raehal et al., 2005) . These early studies ignited efforts to discover or develop opioids which exclusively activate G-protein signaling without also eliciting β-arrestin recruitment. Such G-protein biased small molecules, like TRV130 (DeWire et al., 2013) and PZM21 (Manglik et al., 2016) , have recently been synthesized and indeed appear to possess a reduced side effect profile. Gprotein biased opioids also appear to occur naturally, as revealed by the pharmacological characterization of opioids found within Mitragynina speciosa (kratom) (Varadi et al., 2016) .
Additionally, naturally occurring opioids can serve as the basis of G-protein-biased semisynthetic opioids, as is the case for herkinorin which is derived from naturally occurring salvinorin (Groer et al., 2007) .
In 2001 peptides were identified from spinach rubisco (ribulose-1,5-bisphosphate carboxylase/oxygenase), a 557 kDa enzyme highly common in photosynthetic organisms, and it was found that two rubisco peptides YPLDL (rubiscolin-5) and YPLDLF (rubsicolin-6) have micromolar affinity and potency at δ opioid receptors (δ-ORs) in vitro. Interestingly a study investigating the effect of rubiscolin on skin inflammation also found that rubiscolin-6 prevented -OR internalization (Chajra et al., 2015) . Internalization of δ-ORs tends to be correlated with β-arrestin recruitment (Pradhan et al., 2009) , and thus the aforementioned reduction of -OR internalization with rubiscolin-6 may suggest that rubiscolin peptides do not recruit β-arrestin to -ORs. This led us to hypothesize that these rubiscolin peptides possess Gprotein-bias when compared with the enkephalin and deltorphin-classes of peptides, which are known to recruit β-arrestin (Chiang et al., 2016; Molinari et al., 2010) . Using cellular signaling assays we identified that the rubiscolin peptides indeed have a lower propensity to recruit βarrestin than leu-enkephalin and deltorphin II, while acting as full agonists in a G-proteinmediated cAMP assay. Cell culture and biased signaling assays: cAMP inhibition and β-arrestin-2 recruitment assays were performed as previously described (Chiang et al., 2016) . In brief, for cAMP were calculated using leu-enkephalin as the reference compound.
Methods

Drugs and chemicals
Results
Synthesis of rubiscolin peptides. The rubiscolin, deltorphin II and leu-enkephalin peptides can all be found in nature ( Figure 1A) , however to ensure purity of the rubsicolin peptides, we elected to synthesize rather than extract these peptides [see methods for details]. HPLC-MS analysis of the produced rubiscolin 5 and 6 peptides revealed single, sharp elution peaks with >99% purity (RT = 5.68 and 6.19 minutes, respectively) displaying mass spectra with parent peaks characteristic of the [M+H] + ions of our desired products (m/z = 620.4 and 767.4 for rubiscolins 5 and 6, respectively), enabling their use in cellular assays to characterize their pharmacology (Figure 1B) .
the hydrophobic phenylalanine of leu-enkephalin, and the presence of a bulky, hydrophobic leucine in place of leu-enkephalin's glycine ( Figure 1C) . Interestingly, deltorphin II shows similar features to the rubiscolin compounds in this area with an acidic glutamate and hydrophobic phenylalanine ( Figure 1C) .
Rubiscolin peptides are G-protein-biased δ-OR agonists.
In order to determine the signaling properties of rubiscolin peptides at the δ-OR, we first confirmed that rubiscolin peptides indeed bind to the δ-OR with radioligand binding using membranes prepared from the PathHunter cells. We compared the affinity of the rubiscolin peptides to the highly potent and selective δ-OR peptides deltorphin II and leu-enkephalin.
Deltorphin II displayed the strongest affinity for the δ-OR followed by leu-enkephalin, rubiscolin-6 and rubiscolin-5 (Figure 2A, Table 1 ). Affinity of peptide agonists for the δ-OR is depicted as the pKi, which is a negative log value of the Ki, which is the concentration at which 50% of the δ-OR are occupied by the peptide.
Potency and efficacy (α, normalized to leu-enkephalin) for the δ-OR peptide agonists to inhibit cAMP production is depicted as concentration of 50% inhibition (pIC50) and the SEM.
Potency (pEC50) and efficacy (α, normalized to leu-enkephalin) of δ-OR agonists to recruit βarrestin 1 and 2 are depicted with SEM. The number of repetitions for each drug is indicated in parentheses. Table 1 for details).
Affinity
Next we confirmed that all four peptides were indeed agonists able to inhibit forskolin-induced cAMP production by activation of the inhibitory Gαi-protein pathway. All four peptides displayed full agonism and followed the same rank order in potency as seen for affinity ( Figure   2B, Table 1 ). Next, we assessed the ability of these peptides to recruit β-arrestin, finding that deltorphin II and leu-enkephalin recruit both β-arrestin 1 (Figure 2C ) and β-arrestin 2 ( Figure   2D) , with deltorphin II showing a higher potency (Table 1) . Interestingly, in both assays β-arrestin recruitment induced by the rubiscolins ranged from low to undetectable even at concentrations of 316 µM (Figure 2C and 2D) . Importantly, because the PathHunter cell line was used for our binding studies, this limited β-arrestin recruitment cannot be attributed to a lack of binding to the -OR.
Discussion
Delta opioid receptor peptides like leu-enkephalin, DPDPE and DADLE are all largely unbiased; still, G-protein biased synthetic δ-OR peptides have been produced over 10 years ago as exemplified by UFP-512 (Chiang et al., 2016; Molinari et al., 2010) . We find that deltorphin II has a bias towards β-Arrestin recruitment ( Table 2 , bias factor < 1).
Distinguishingly, here we present the first report of rubiscolin-5 and rubiscolin-6 as naturallyoccurring G-protein-biased δ-OR peptides, with both peptides have bias factors >> 1 ( Table   2) . Which is unsurprising since we did not clearly detect significant rubiscolin-5 induced βarrestin recruitment to the δ-OR at concentrations as high as 2mM (Figure 2C and D) . In terms of opioid receptor pharmacology, studies thus far have highlighted the benefits of biased signaling that favors G-protein over β-arrestin. For µ-ORs, G-protein biased signaling may reduce tolerance, constipation and respiratory depression (DeWire et al., 2013; Manglik et al., 2016) , although recent studies have placed some doubts about the strength of this hypothesis (Altarifi et al., 2017; Hill et al., 2018) . For the κ-ORs, G-protein biased ligands may avoid aversive effects commonly associated with (unbiased) κ-OR agonists (Bruchas et al., 2007; Land et al., 2009) . For the -ORs β-arrestin recruitment has been associated with increased alcohol use, whereas G-protein-biased -OR agonists reduce alcohol intake in mice (Chiang et al., 2016; Robins et al., 2018) .
Currently only an antagonist-bound -OR structure has been resolved, in contrast to κ-ORs and µ-ORs for which agonist-bound structures are available. Still, although less optimal, homology modeling can be performed to use the agonist-bound OR structures to create a computational model of an agonist bound conformation of the -OR. Recent studies using computational modeling and X-ray crystallography have suggested that drug conformation can have a significant impact on specific receptor conformations inducing receptor states that are more or less susceptible to recruit β-arrestin (McCorvy et al., 2018; Wacker et al., 2017) . While common substructure analysis did not show major differences in conformation between rubiscolin-5 and leu-enkephalin or deltorphin II, it is noteworthy that the rubiscolin peptides contain a proline residue. Proline residues, due to their cyclic structure are known to induce kinks and instill a degree of inflexibility to the peptide. It is possible that this proline residue in rubiscolins induces a certain conformation that the more flexible enkephalin and deltorphin II circumvent. With our finding that rubiscolin peptides are G-protein-selective -OR agonists, it may be of interest to dock rubiscolin-6, or YPLDLV a more potent and -OR-selective synthetic analog (Yang et al., 2003b) to potentially obtain insight into which regions of the -
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OR are being engaged or spared to confer G-protein selectivity onto rubiscolin when compared with deltorphin II or leu-enkephalin.
Rubsicolin-6 is more potent and has stronger affinity for the -OR than rubiscolin-5, but both peptides are rather weak in comparison to leu-enkephalin and deltorphin II, which may limit their therapeutic potential. One advantage however of the rubisocolin peptides is their oral bioavailability; rubiscolins are produced by digestive pepsin cleavage of rubisco, and rubiscolin-6 at a dose of 100 mg/kg, p.o. produced analgesia in a tail-pinch assay (Yang et al., 2001) , enhanced memory consolidation, (Yang et al., 2003a) and reduced anxiety-like behavior (Hirata et al., 2007) in a manner that was shown to be reversible by the -OR antagonist naltrindole, suggesting that the behavior was -OR mediated.
Rubiscolin-6 has been reported to produce an orexigenic response (Kaneko et al., 2012a; Kaneko et al., 2014; Kaneko et al., 2012b) by acting at -ORs, however DPDPE, a peptide which recruits β-arrestin on par with enkephalin, produces a similar physiological response (Kaneko et al., 2014) , suggesting that the G-protein-selective nature of rubiscolin-6 may not be a contributing factor to this physiological response.
Overall, we provide evidence for the first known naturally-occurring, orally bioavailable G-protein-selective -OR peptide agonist. The attributes of rubiscolin-6 may make it an interesting drug in treating alcohol use disorder (Chiang et al., 2016; Robins et al., 2018) , or as an analgesic with fewer side effects.
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